Detection reagent kit for early ovarian cancer diagnosis

Abstract

The invention provides a detecting reagent knit used for detecting an early oophoroma diagnosis, which is composed of a ninety-six-hole polystyrene ELISA plate, a peroxydase labeled object, a mouse anti-human CCL18 single clone antibody, a mouse anti-human CXCL1 single clone antibody, a rabbit anti-human CCL18 polyclonal antibody, a rabbit anti-human CXCL1 polyclonal antibody, a development liquid, a stopping liquid, a titer and a cover board film. The reagent knit uses an oophoroma serum marker CCL18 and an oophoroma serum marker CXCL2. The reagent knit can be used for detecting benign and malign ovarian tumors, especially detecting early oophoroma.

Description

1. Technical field [0001] The invention relates to the field of biological and medical detection. In particular, it relates to a detection kit for early ovarian cancer diagnosis. 2. Background technology [0002] Ovarian malignant tumor is a common gynecological malignant tumor at home and abroad, and its mortality rate has accounted for the fourth of all female malignant tumors. Although in the past 20 years, people have made considerable efforts in treatment, including the discovery of new drugs and programs. , Improvement of surgery. However, the mortality rate ranks first among gynecological malignancies, and the five-year survival rate is only about 30%. One of the important reasons causing its high mortality rate is the lack of means of early diagnosis, and 70% of the patients are late patients when they are first diagnosed. Although a variety of new ovarian tumor markers and new diagnostic methods for ovarian malignant tumors emerge in endlessly, due to the lack of...

AI Technical Summary

Problems solved by technology

Although a variety of new ovarian tumor markers and new diagnostic methods for ovarian malignant tumors emerge in endlessly, due to the lack of obvious early symptoms of ovarian malignant tumors, surgical operations and physical imaging detection are expensive and time-consuming, resulting in patients with no symptoms and no family history. Diagnosis and screening methods for early ovarian malignancies in women are still unsatisfactory

So far, there is no effective serum marker for individual screening and early diagnosis, including the diagnostic specificity and sensitivity of serum CA125 for stage I ovarian malignancies is only about 25%-30%. Therefore, early detection, Early diagnosis of ovarian malignancies is of great significance to improve the prognosis of patients with ovarian malignancies

Images